Latest
Surf Therapeutics Receives Jetstream Venture Fund Investment to Advance Ultrasound Neuromodulation for Rheumatoid ArthritisSurf Therapeutics Receives Jetstream Venture Fund Investment to Advance Ultrasound Neuromodulation for Rheumatoid Arthritis|Hill Research Receives Jetstream Venture Fund Investment to Scale AI for Clinical Trial OperationsHill Research Receives Jetstream Venture Fund Investment to Scale AI for Clinical Trial Operations|Tiger Global Invests in PopUp Bagels at $300M Valuation as Brand Expands NationallyTiger Global Invests in PopUp Bagels at $300M Valuation as Brand Expands Nationally|Collide Capital Raises $95M Fund II to Back Early-Stage Startups in Fintech, Supply Chain, and Future of WorkCollide Capital Raises $95M Fund II to Back Early-Stage Startups in Fintech, Supply Chain, and Future of Work|pH7 Technologies Raises $32M Series B to Scale Critical Mineral Extraction From Waste StreamspH7 Technologies Raises $32M Series B to Scale Critical Mineral Extraction From Waste Streams|Palm Receives Amex Ventures Investment to Build Business Identity Infrastructure for Financial ServicesPalm Receives Amex Ventures Investment to Build Business Identity Infrastructure for Financial Services|LiveOak Fiber Secures $425M Credit Facility to Expand Fiber Broadband Across Georgia and FloridaLiveOak Fiber Secures $425M Credit Facility to Expand Fiber Broadband Across Georgia and Florida|Citra Space Raises $15M Series A to Build Space Object Identification and Orbital Intelligence TechnologyCitra Space Raises $15M Series A to Build Space Object Identification and Orbital Intelligence Technology|Critical Loop Raises $26M Series A to Deliver Industrial Power and Microgrids in Weeks Instead of YearsCritical Loop Raises $26M Series A to Deliver Industrial Power and Microgrids in Weeks Instead of Years|Slate Auto Raises $650M Series C to Scale Affordable Electric Truck Production in the U.S.Slate Auto Raises $650M Series C to Scale Affordable Electric Truck Production in the U.S.|Surf Therapeutics Receives Jetstream Venture Fund Investment to Advance Ultrasound Neuromodulation for Rheumatoid ArthritisSurf Therapeutics Receives Jetstream Venture Fund Investment to Advance Ultrasound Neuromodulation for Rheumatoid Arthritis|Hill Research Receives Jetstream Venture Fund Investment to Scale AI for Clinical Trial OperationsHill Research Receives Jetstream Venture Fund Investment to Scale AI for Clinical Trial Operations|Tiger Global Invests in PopUp Bagels at $300M Valuation as Brand Expands NationallyTiger Global Invests in PopUp Bagels at $300M Valuation as Brand Expands Nationally|Collide Capital Raises $95M Fund II to Back Early-Stage Startups in Fintech, Supply Chain, and Future of WorkCollide Capital Raises $95M Fund II to Back Early-Stage Startups in Fintech, Supply Chain, and Future of Work|pH7 Technologies Raises $32M Series B to Scale Critical Mineral Extraction From Waste StreamspH7 Technologies Raises $32M Series B to Scale Critical Mineral Extraction From Waste Streams|Palm Receives Amex Ventures Investment to Build Business Identity Infrastructure for Financial ServicesPalm Receives Amex Ventures Investment to Build Business Identity Infrastructure for Financial Services|LiveOak Fiber Secures $425M Credit Facility to Expand Fiber Broadband Across Georgia and FloridaLiveOak Fiber Secures $425M Credit Facility to Expand Fiber Broadband Across Georgia and Florida|Citra Space Raises $15M Series A to Build Space Object Identification and Orbital Intelligence TechnologyCitra Space Raises $15M Series A to Build Space Object Identification and Orbital Intelligence Technology|Critical Loop Raises $26M Series A to Deliver Industrial Power and Microgrids in Weeks Instead of YearsCritical Loop Raises $26M Series A to Deliver Industrial Power and Microgrids in Weeks Instead of Years|Slate Auto Raises $650M Series C to Scale Affordable Electric Truck Production in the U.S.Slate Auto Raises $650M Series C to Scale Affordable Electric Truck Production in the U.S.
Back to articles
Jesse Landry

Remission Medical Raises Funding to Expand Virtual Rheumatology Platform for Health Systems

Funding Details

Amount

$5M

Round

Series A

Rheumatology is one of those corners of healthcare where time drags and outcomes follow. Demand stacks up, specialists stay scarce, and patients end up negotiating with the calendar instead of getting care. That gap is not theoretical. It is operational. Blake Wehman, CEO, lived it, studied it, and then decided to build something that does not wait around for the system to fix itself.

Remission Medical just pulled in $5M in Series A funding, led by Blue Heron Capital, and the signal here is louder than the number. This is a Richmond-born company, grounded in lived experience and sharpened inside health systems, now scaling a model that meets providers where they already operate. Not another shiny layer on top. This one plugs straight into the bloodstream.

Blake Wehman, CEO, took an operations mindset and paired it with a personal story that does not need dramatics to land. The result is a virtual-first rheumatology platform that embeds directly into health systems, using their workflows, their EMRs, their contracts. Translation: no extra friction, no theatrical handoffs, just more capacity where there was none. Tyler Beard, CTO, is the one making sure that engine runs clean, with RemissionOS quietly coordinating the moving parts behind the curtain.

And that is where it gets interesting. This is not telehealth dressed up for headlines. This is a workforce model, tuned for reality. Advanced practice providers, supervised by board-certified rheumatologists, deployed with precision. Patient-reported outcomes feeding the system. Generative intelligence shaping care pathways without trying to steal the spotlight. It is less about replacing doctors and more about extending them, which is exactly what the market has been begging for.

Blue Heron Capital stepping in as lead tells you this is not a science project. It is a bet on execution. No inflated promises, no mystery metrics, just a clear read on a broken supply-demand curve and a team that knows how to bend it back into shape.

Dr. Kyle Harner, CMO, bringing 20+ years of clinical depth. Blake Siewert, CRO, pushing revenue with intention. Michael Spine, Chief Growth Officer, driving partnerships where they actually convert. Matt Hogan, VP of Business Development, building the bridges that make health systems say yes instead of maybe. It is a lineup that understands that access is not an idea, it is logistics.

The quiet part that should not stay quiet is this: embedding beats overlaying. Health systems do not need more tabs open. They need throughput, outcomes, and something that respects how care actually gets delivered.